EditorialEditorial
If You Want to Perform a Relevant Cost-effectiveness Trial, First Do a Modeling Study
Wietske Kievit and Alfons A. den Broeder
The Journal of Rheumatology March 2021, jrheum.201430; DOI: https://doi.org/10.3899/jrheum.201430
Wietske Kievit
W. Kievit, PhD, Assistant Professor in Health Technology Assessment, Radboud University Medical Centre, Radboud Institute for Health Science, Department for Health Evidence, Nijmegen; A.A. den Broeder, MD, PhD, Rheumatologist and Epidemiologist, Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands. AdB receives congress visit invitations from AbbVie, Roche, and Biogen; expert witness fees from BMS, BI, Amgen, and Fresenius; and study funding from Lilly, AbbVie, Pfizer, and Novartis. WK declares no conflicts of interest. Address correspondence to Dr. W. Kievit, Radboud UMC, Department for Health Evidence (133), PO Box 9101, 6500HB Nijmegen, the Netherlands. Email: wietske.kievit@radboudumc.nl.
Alfons A. den Broeder
W. Kievit, PhD, Assistant Professor in Health Technology Assessment, Radboud University Medical Centre, Radboud Institute for Health Science, Department for Health Evidence, Nijmegen; A.A. den Broeder, MD, PhD, Rheumatologist and Epidemiologist, Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands. AdB receives congress visit invitations from AbbVie, Roche, and Biogen; expert witness fees from BMS, BI, Amgen, and Fresenius; and study funding from Lilly, AbbVie, Pfizer, and Novartis. WK declares no conflicts of interest. Address correspondence to Dr. W. Kievit, Radboud UMC, Department for Health Evidence (133), PO Box 9101, 6500HB Nijmegen, the Netherlands. Email: wietske.kievit@radboudumc.nl.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
If You Want to Perform a Relevant Cost-effectiveness Trial, First Do a Modeling Study
Wietske Kievit, Alfons A. den Broeder
The Journal of Rheumatology Mar 2021, jrheum.201430; DOI: 10.3899/jrheum.201430